文献速递中医内科中药与中成药合理使用

肾衰II号方通过激活Nrf2抑制缺氧诱导的氧化应激与铁死亡改善CKD肾纤维化

Shen-Shuai-II-Recipe suppresses hypoxia-induced oxidative stress and ferroptosis via Nrf2 activation to ameliorate renal fibrosis in chronic kidney disease.
PubMed 文献 · J Ethnopharmacol · 2025-10-24

肾衰II号方(SSR)是临床治疗慢性肾脏病(CKD)的有效中药复方。本研究在大鼠5/6肾切除/梗死模型和慢性缺氧NRK-52E细胞中探讨其机制,发现SSR可减轻肾脏缺氧、氧化应激和铁死亡并改善纤维化,其作用与上调Nrf2蛋白、激活Keap1-Nrf2/xCT/GPX4轴有关,Nrf2抑制剂可削弱该效应。

要点

  • SSR在CKD大鼠中减轻缺氧、氧化应激、铁死亡和肾纤维化。
  • SSR通过激活Keap1-Nrf2/xCT/GPX4轴增强抗氧化能力。
  • Nrf2抑制剂ML385可削弱SSR对缺氧细胞的保护作用。

核心结论

  • SSR通过激活Nrf2抑制缺氧诱导的氧化应激和铁死亡,从而改善CKD肾纤维化。

研究设计与样本

  • 体内建立5/6肾切除/梗死(A/I)CKD大鼠模型,给予SSR或氯沙坦治疗八周。
  • 体外对NRK-52E细胞进行慢性缺氧诱导,并用SSR含药血清和(或)Nrf2 inhibitor(ML385)处理。
  • 采用血氧水平依赖MRI、组织病理学、比色法、免疫印迹和荧光法评估肾脏缺氧、氧化应激、铁死亡和纤维化。

主要发现

  • SSR显著抑制5/6(A/I)肾脏的氧化应激和铁死亡,同时减轻缺氧和纤维化,并上调Nrf2蛋白表达。
  • 缺氧NRK-52E细胞中纤维化和缺氧相关蛋白呈时间依赖性增加,Nrf2通路受抑制。
  • SSR通过激活Keap1-Nrf2/xCT/GPX4轴改善慢性缺氧NRK-52E细胞的抗氧化能力、减轻脂质过氧化和纤维化,而Nrf2抑制后该效应减弱。

临床怎么用

  • SSR作为临床有效中药复方,其肾脏保护作用机制涉及Nrf2激活,支持在CKD中针对缺氧-氧化应激-铁死亡轴的治疗思路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Shen-Shuai-II-Recipe (SSR), a clinically effective Chinese herbal formula for chronic kidney disease (CKD) management, has shown potential anti-hypoxia and anti-fibrosis properties in rat models of CKD. However, the underlying molecular mechanisms of its renoprotection warrant further elucidation. AIM OF THE STUDY: This study investigated the mechanisms of SSR's renoprotective actions under chronic hypoxia condition of CKD. MATERIALS AND METHODS: In vivo, 5/6 renal ablation/infarction (A/I) rat models of CKD were established and administered with SSR or losartan for eight weeks. In vitro, NRK-52E cells underwent chronic hypoxia induction and were treated with SSR-medicated serum and (or) Nrf2 inhibitor (ML385). Renal hypoxia, oxidative stress, ferroptosis, and fibrosis were assessed via blood oxygenation level-dependent MRI, histopathology, colorimetry, immunoblotting, and fluorometry. RESULTS: SSR significantly suppressed oxidative stress and ferroptosis in 5/6 (A/I) kidneys, concomitant with alleviated hypoxia and fibrosis, which was associated with the up-regulated expression of Nrf2 protein. Hypoxic NRK-52E cells exhibited time-dependent increases in fibrosis and hypoxia-related proteins and suppression of the Nrf2 pathway. Furthermore, SSR significantly improved antioxidant capacity, attenuated lipid peroxidation and fibrosis in chronic hypoxia induced NRK-52E cells by activating the Keap1-Nrf2/xCT/GPX4 axis, while the effect was diminished by Nrf2 inhibition. CONCLUSIONS: SSR inhibits hypoxia-induced oxidative stress and ferroptosis to ameliorate renal fibrosis in CKD via Nrf2 activation.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Xu Y, Wang M, Wang L, et al. Shen-Shuai-II-Recipe suppresses hypoxia-induced oxidative stress and ferroptosis via Nrf2 activation to ameliorate renal fibrosis in chronic kidney disease. J Ethnopharmacol. 2025. PMID: 41139039. doi:10.1016/j.jep.2025.120783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。